Literature DB >> 21775520

Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.

Yujian Zhang1, Oleg Chertov, Jingli Zhang, Raffit Hassan, Ira Pastan.   

Abstract

Mesothelin is a cell-surface tumor-associated antigen expressed in several human cancers. The limited expression of mesothelin on normal tissues and its high expression in many cancers make it an attractive candidate for targeted therapies using monoclonal antibodies, immunoconjugates, and immunotoxins. Mesothelin is actively shed from the cell surface and is present in the serum of patients with malignant mesothelioma, which could negatively affect the response to these therapies. We have found that mesothelin sheddase activity is mediated by a TNF-α converting enzyme (TACE), a member of the matrix metalloproteinase/a disintegrin and metalloprotease family. We showed that EGF and TIMP-3 act through TACE as endogenous regulators of mesothelin shedding. We also found that reducing shedding significantly improved the in vitro cytotoxicity of immunotoxin SS1P, which targets mesothelin and is currently in clinical trials for the treatment of patients with mesothelioma and lung cancer. Our findings provide a mechanistic understanding of mesothelin shedding and could help improve mesothelin-based targeted therapies. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775520      PMCID: PMC3165076          DOI: 10.1158/0008-5472.CAN-11-0466

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  The shedding activity of ADAM17 is sequestered in lipid rafts.

Authors:  Edwige Tellier; Matthias Canault; Laure Rebsomen; Bernadette Bonardo; Irène Juhan-Vague; Gilles Nalbone; Franck Peiretti
Journal:  Exp Cell Res       Date:  2006-09-05       Impact factor: 3.905

2.  Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.

Authors:  Belén Santiago-Josefat; Cary Esselens; Joan Josep Bech-Serra; Joaquín Arribas
Journal:  J Biol Chem       Date:  2007-01-16       Impact factor: 5.157

Review 3.  Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors.

Authors:  Elisa Nuti; Tiziano Tuccinardi; Armando Rossello
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

4.  Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.

Authors:  Carole Sapede; Anne Gauvrit; Isabelle Barbieux; Martine Padieu; Laurent Cellerin; Christine Sagan; Arnaud Scherpereel; Gérard Dabouis; Marc Grégoire
Journal:  Cancer Sci       Date:  2007-12-27       Impact factor: 6.716

5.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

6.  Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Authors:  Raffit Hassan; Susie Bullock; Ahalya Premkumar; Robert J Kreitman; Hedy Kindler; Mark C Willingham; Ira Pastan
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

7.  Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.

Authors:  Yujian Zhang; Laiman Xiang; Raffit Hassan; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205

8.  Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases.

Authors:  Linda Troeberg; Kazunari Fushimi; Rama Khokha; Hervé Emonard; Peter Ghosh; Hideaki Nagase
Journal:  FASEB J       Date:  2008-07-16       Impact factor: 5.191

9.  Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17.

Authors:  Cary W Esselens; Jordi Malapeira; Núria Colomé; Marcia Moss; Francesc Canals; Joaquín Arribas
Journal:  Biol Chem       Date:  2008-08       Impact factor: 3.915

10.  Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.

Authors:  Raffit Hassan; V Courtney Broaddus; Shannon Wilson; David J Liewehr; Jingli Zhang
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

View more
  20 in total

1.  A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas.

Authors:  Sherrill L Macura; Jedd M Hillegass; Jeremy L Steinbacher; Maximilian B MacPherson; Arti Shukla; Stacie L Beuschel; Timothy N Perkins; Kelly J Butnor; Melissa J Lathrop; Mutlay Sayan; Khan Hekmatyar; Douglas J Taatjes; Risto A Kauppinen; Christopher C Landry; Brooke T Mossman
Journal:  J Histochem Cytochem       Date:  2012-06-21       Impact factor: 2.479

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 3.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Authors:  Raffit Hassan; Anish Thomas; Christine Alewine; Dung T Le; Elizabeth M Jaffee; Ira Pastan
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  A new anti-mesothelin antibody targets selectively the membrane-associated form.

Authors:  Kamal Asgarov; Jeremy Balland; Charline Tirole; Adeline Bouard; Virginie Mougey; Diana Ramos; António Barroso; Vincent Zangiacomi; Marine Jary; Stefano Kim; Maria Gonzalez-Pajuelo; Bernard Royer; Hans de Haard; Andy Clark; John Wijdenes; Christophe Borg
Journal:  MAbs       Date:  2017-04       Impact factor: 5.857

5.  Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Authors:  Prince Awuah; Tapan K Bera; Messan Folivi; Oleg Chertov; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

Review 6.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701

7.  Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors.

Authors:  Youngshang Pak; Yujian Zhang; Ira Pastan; Byungkook Lee
Journal:  Cancer Res       Date:  2012-05-04       Impact factor: 12.701

8.  Modulating mesothelin shedding to improve therapy.

Authors:  Ira Pastan; Yujian Zhang
Journal:  Oncotarget       Date:  2012-02

9.  Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.

Authors:  Jingli Zhang; Tapan K Bera; Wenhai Liu; Xing Du; Christine Alewine; Raffit Hassan; Ira Pastan
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

10.  Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.

Authors:  Abid R Mattoo; Ira Pastan; David Fitzgerald
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.